Extracorporeal Membrane Oxygenation (ECMO) Machine Market Size, Share & COVID-19 Impact Analysis, By Type (Veno-Arterial, and Veno-Venous), By Application (Adult, Neonatal, and Pediatric), and Regional Forecast, 2023-2030

The global extracorporeal membrane oxygenation (ECMO) machine market size was valued at USD 495.6 million in 2022. The market is expected to grow from USD 513.3 million in 2023 to USD 681.8 million by 2030, exhibiting a CAGR of 4.1% during the forecast period.

Extracorporeal membrane oxygenation is performed to oxygenate the blood outside the body and to offer external circulatory support. Blood oxygenation is performed through extracorporeal membrane oxygenation machines that operate in two modes, VA (veno-arterial) and VV (veno-venous). The procedure is performed in patients undergoing respiratory failure, acute respiratory distress syndrome (ARDS), pulmonary embolism, COVID-19, cardiogenic shock, open-heart surgery, and other respiratory and cardiac disorders. The growing prevalence of respiratory disorders and the COVID-19 pandemic is anticipated to significantly boost the demand for extracorporeal membrane oxygenation machines during the forecast period.

The major factor responsible for market growth is the growing need for long-term circulatory support in chronic respiratory and cardiac disorders. Moreover, technological advancements leading to improved patient outcomes and increasing adoption of extracorporeal membrane oxygenation machines are some other significant factors driving the growth of the market. Furthermore, introduction of emerging technologies by key players to eliminate potential challenges during the process is anticipated to contribute to the market growth during the forecast period.

COVID-19 IMPACT

Increased Use of ECMO Machines During COVID-19 Pandemic Positively Impacted Market Growth

The COVID-19 pandemic has significantly changed the landscape of healthcare practices worldwide and resulted in considerably high growth of the extracorporeal membrane oxygenation machine market in 2020. This is attributed to the vast spread of the virus and the increasing need for these machines to provide circulatory support and save lives. The improved machine outcome in COVID-19 patients led to increased adoption of these machines in hospitals, thereby fueling the demand for extracorporeal membrane oxygenation machines. Owing to the rise in demand, market players witnessed an increased demand for their products during the pandemic.

For instance, Getinge AG, a key player in the market, registered a revenue of USD 3,473.8 million in 2020, an increase of 12.3% compared to 2019. The growth is attributed to the increased demand for these machines in hospitals and centers for COVID-19 patients. For instance, in June 2020, Getinge AB increased the production output of ECMO machines due to strong demand associated with COVID-19.

Thus, the global extracorporeal membrane oxygenation machine market witnessed a tremendous growth in 2021 as compared to 2020.

LATEST TRENDS

Request a Free sample to learn more about this report.

Growing Deployment of ECMO Machines for Other Cardiac and Respiratory Conditions to Propel Industry Expansion

These machines can serve several significant roles in many conditions, which were relatively underutilized in the past. Primary graft dysfunction (PGD) is a critical condition requiring circulatory support. PGD is a syndrome of acute non-immune-mediated injury that usually occurs within 72 hours of lung and heart transplant and is the most common cause of early mortality. Recently, several studies have proven the positive outcome in PGD patients requiring extracorporeal membrane oxygenation support.

According to a study published in March 2022 in the journal of the European Society for Organ Transplantation, VA-ECMO is a salvage therapy for heart transplant recipients with severe PGD in adults, especially in prior cardiac surgery history patients or relatively suboptimal recipient selection.

Using these machines in PGD cases led to a reduction in mortality rate, thereby increasing surgeons’ inclination toward early initiation of patients on these systems.

DRIVING FACTORS

Surging Burden of Cardiovascular and Respiratory Diseases to Boost Market Growth

The rising prevalence of cardiovascular diseases is leading to the increased use of these machines. The prevalent cardiovascular diseases, including coronary heart disease, cerebrovascular disease, rheumatic and congenital heart diseases impose a high disease burden on the healthcare system. These cardiovascular disorders are the leading cause of death worldwide.

According to the World Heart Federation, approximately 18.6 million people die annually from cardiovascular diseases. Furthermore, the growing prevalence of respiratory diseases, such as Acute Respiratory Distress Syndrome (ARDS), chronic obstructive pulmonary diseases, COVID-19, and respiratory failure, is another major factor driving the demand for these machines.

• For instance, according to an article published by the European Respiratory Society, approximately 4,600 lung transplant procedures are performed globally. North America and Europe account for around 80% of the total procedures.

Additionally, as per data published by American Lung Association, about 190,000 Americans are diagnosed with ARDS annually in the U.S. Such increasing prevalence of cardiovascular and respiratory diseases has boosted the demand for these machines and is driving the extracorporeal membrane oxygenation machine market growth.

Rising Technological Advancements Leading to Increased Product Adoption to Contribute to Market Growth

The miniaturization of the machine’s components, such as the oxygenator and hollow pumps, which are used in various surgeries, aids in transporting critical patients. Additionally, the introduction of technologically advanced components, such as improved rotary pumps, dual lumen cannula, innovative oxygenators, and new cannulation approaches, is anticipated to ease the use of extracorporeal membrane oxygenation (ECMO) machines. The advantages offered by new products compared with older devices include rapid priming time, lower priming volume, low blood flow resistance, and diminished plasma leakage, which may reduce platelet consumption and activation. Also, in advanced circuits, surface coatings that mimic the endothelial lining of blood vessels, reduce thrombogenicity, obviate the need for continuous anticoagulation, and reduce the incidence of related complications.

• For instance, in July 2022, Inspira Technologies OXY B.H.N. Ltd. introduced the "Liby" System, an advanced life support system used to treat patients with life-threatening heart and lung failure.

Similar advancements and the introduction of new products are expected to drive market growth in the coming years.

RESTRAINING FACTORS

High Cost of the Systems Challenges Affordability to Limit the Market Growth

The cost of an ECMO run includes machines cost, consumable costs, and cost of operator and other medical human resources. Among all, the machine’s cost puts significant pressure on the affordability of the healthcare system in developing nations and limits its adoption. For instance, in India, the extracorporeal membrane oxygenation machine costs around USD 35,000 to USD 48,000.

The cost of one system ranges between USD 152,000 to USD 170,000 in the U.S., and USD 35,500 to USD 47,300 in the U.K. The final cost of the procedure is at the higher end and the procedure use is impacted by limited healthcare expenditure in several nations.

SEGMENTATION

By Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Veno-Arterial Segment to Dominate the Market Owing to Increasing Product Adoption

Based on type, the market is categorized into veno-arterial, and veno-venous. Veno-Arterial segment held the largest share in 2022 and is projected to grow with a notable CAGR during the forecast timeframe. The dominant share of this segment is due to factors such as wide applications offered by this device type, favorable reimbursement policies, and the increasing prevalence of cardiac disorders.

• For instance, according to the American Academy of Pediatrics, about one infant in every 100 is born with a congenital heart defect (CHD), and 25% of those are expected to have a critical CHD (CCHD). Thus, the growing prevalence of cardiac failure is projected to increase the demand for veno-arterial machines.

The Veno-Venous segment is expected to grow substantially during the forecast period. The segment's growth is attributed to the surge in the use of veno-venous systems during the COVID-19 pandemic and the increasing prevalence of respiratory disorders, which is increasing the demand for veno-venous systems.

• For instance, according to an article published in British Medical Journal in April 2022, veno-venous systems were used in COVID-19-associated respiratory failure patients. The study outcome revealed that using veno-venous systems reduced mortality by 7.1% compared to conventional mechanical ventilation without ECMO.

The COVID-19 infection, coupled with several other respiratory disorders, encouraged the use of veno-venous systems in recent years and is expected to boost the segment’s growth during the forecast period.

By Application Analysis

Adult Segment to Hold Major Market Share Due to High Diseases Prevalence in Adult Population

Based on application, the market is segmented into adult, pediatric, and neonatal.

The adult segment dominated the market in 2022 and is expected to register a substantial CAGR during the forecast period. The segment growth is attributed to high COVID-19 cases and an increasing number of lung transplants in the adult population only.

• For instance, according to ELSO registry in October 2022, the total number of the runs performed in the adult population was 84,113 in cardiac and pulmonary through 2021.

The pediatric segment is anticipated to grow at a substantial CAGR during the forecast period (2023-2030). The high growth rate is due to various factors such as the rising prevalence of pneumonia and cardiac illness.

• For instance, according to UNICEF, a child dies of pneumonia every 43 seconds. Additionally, pneumonia causes more deaths in children than any other infectious disease, which is around 2,000 every day.

The neonatal segment witnessed comparatively low growth during the forecast period. The factors attributed to limited growth are complications associated with the process in neonates.

• For instance, as per ELSO, in neonatal respiratory failure, mechanical complications, bleeding, hypertension, seizure, and renal failure are the most common complications of neonatal ECMO.

Thus, such increasing incidence and prevalence of respiratory conditions among all age groups, mainly in adults, are anticipated to contribute to market growth during the forecast timeframe.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

In terms of region, the North America market was valued at USD 243.5 million in 2022. The region dominated the global market in 2022 and is expected to continue its dominance throughout the forecast period. The market growth across the region is primarily attributed to the rising number of surgical procedures. Moreover, the strong presence of key market players and the high prevalence of cardiac disorders in the U.S. contribute to the region's market growth.

• For instance, according to the CDC, in the U.S., a person dies every 34 seconds from cardiovascular disease. Also, in 2020, about 697,000 people in the U.S. died from heart disease.

Europe is anticipated to expand at a substantial CAGR during the forecast period (2023-2030). The growth is due to the increasing public and private investment in R&D, demand for healthcare devices, and favorable reimbursement policies.

• For instance, in June 2018, Med Tech Reimbursement Consulting (MTRC) released a European reimbursement report in 11 countries for extracorporeal membrane oxygenation systems. The analysis includes indications such as acute respiratory distress syndrome, deterioration of chronic advanced heart failure, postcardiotomy cardiogenic shock, and post-myocardial infarction cardiogenic shock.

The Asia Pacific market is expected to expand at the highest CAGR during the estimated period (2023-2030). The highest CAGR is attributed to the large patient population, the opening of new ECMO centers, and the growing start-up culture in developing countries. According to ELSO data, the APAC region currently possesses more than 100 ECMO centers, which is anticipated to increase in the coming years.

The market in Latin America, and Middle East & Africa, is expected to expand at a moderate CAGR during the forecast period. This is attributable to the factors such as the improved healthcare infrastructure in emerging economies and increasing adoption of these devices.

KEY INDUSTRY PLAYERS

Companies Focus on Enhancing their Product Portfolio to Strengthen Market Share

The market is consolidated, as key companies, such as Getinge AB, Terumo Corporation, and Medtronic plc, accounted for most of the global Extracorporeal Membrane Oxygenation machine market share in 2022.

Getinge AB held the highest share of the market in 2022. The leading position of the company in the market is due to its strong portfolio of extracorporeal membrane oxygenation machines and consumables. Moreover, a wide distribution network contributes to the company's large share in the market.

Terumo Corporation held the significant market share in 2022. Increasing preference for the company’s cardiovascular products by the healthcare professionals, mainly in Japan and other Asian countries, positively influences the company’s position in the market. 

LIST OF KEY COMPANIES PROFILED:

• Getinge AB (Sweden)


• LivaNova PLC (U.K.)


• Medtronic (Ireland)


• Terumo Corporation (Japan)


• Xenios AG (Fresenius Medical Care AG & Co. KGaA) (Germany)


• EUROSETS (Italy)


• ABIOMED (U.S.)


• NIPRO (Japan)


• Spectrum Medical (U.K.)

KEY INDUSTRY DEVELOPMENTS:

• November 2022 - LivaNova PLC announced the FDA clearance for LifeSPARC. The company received 510(k) approval for its next-generation advanced circulatory support system.


• May 2022 - Livanova PLC announced the acquisition of Pittsburgh-based biotechnology company ALung Technologies Inc. to strengthen its market position.


• October 2021 - MicroPort Scientific Corporation acquired German Extracorporeal life support (ECLS) company Hemovent GmbH and invested in expanding the company’s German operations.


• January 2021 - EUROSETS announced the commercial release of ECMOLife, an extracorporeal life support system with an outstanding magnetic levitation centrifugal pump. The product was commercialized out of the U.S.


• April 2020 – ABIOMED announced the acquisition of a medical device company Breethe. Breethe developed a portable Extracorporeal Membrane Oxygenation system that oxygenates and removes CO₂ from patient’s blood in cardiogenic shock or respiratory failure. 

REPORT COVERAGE

An Infographic Representation of Extra Corporeal Membrane Oxygenation (ECMO) Market

View Full Infographic

To get information on various segments, share your queries with us

The research report provides an in-depth industry analysis. It focuses on segments such as type and application. Besides this, it offers insights related to the impact of COVID-19, market trends, and the number of heart and lung transplants performed in key countries. Additionally, the report consists of several factors contributing to industry growth. The report also provides the competitive landscape of the market.

Report Scope & Segmentation